From Acquired to Inherited: Understanding CSF3R-Related Neutrophilia — CNL and Its Hereditary Counterpart
A persistently high neutrophil count is one of the most common findings on a routine blood report — and one of the most commonly misread. Most clinicians default to infection, inflammation, or a reactive process. But there are two other explanations that are far rarer, far more specific, and both come down to the same gene: CSF3R.
One is Chronic Neutrophilic Leukemia (CNL) — a rare, acquired blood cancer. The other is Hereditary CSF3R Neutrophilia — a familial trait present from birth. They can look identical on paper. Telling them apart changes everything about how a patient and their family are counseled, monitored, and treated. This piece walks through both, in sequence, starting with the acquired form.
Part 1: Chronic Neutrophilic Leukemia (CNL)
What Is CNL?
CNL belongs to a family of blood cancers called myeloproliferative neoplasms (MPNs) — conditions where the bone marrow produces too many of a particular blood cell type. In CNL’s case, the overproduced cell is the neutrophil, the immune system’s frontline defender against infection.
Unlike chronic myeloid leukemia (CML), which is driven by the well-known Philadelphia chromosome and the BCR-ABL1 fusion gene, CNL is BCR-ABL1-negative. This distinction matters enormously for diagnosis: CNL can look like a bad infection or a reactive high white count on a routine blood report, and it’s often only correctly identified after other causes have been ruled out and specific genetic testing is done.
CNL is genuinely uncommon. Only around 200 cases had been formally reported worldwide as of 2019, and the true global incidence remains unknown. Most patients are diagnosed around age 66, with a slight male predominance.
Symptoms to Watch For
CNL’s presentation ranges from completely silent to significantly symptomatic:
- No symptoms at all — many cases are caught incidentally on a routine complete blood count (CBC)
- Enlarged spleen (splenomegaly) — the single most consistent physical finding, sometimes causing abdominal fullness, bloating, or early satiety
- Enlarged liver (hepatomegaly)
- Fatigue
- Itching (pruritus)
- Easy bruising, bleeding tendencies, or purpura
- Bone pain
- Gout, in some cases
Indian case reports have also highlighted an elevated serum vitamin B12 level as a recurring laboratory clue alongside persistent neutrophilia — a detail worth flagging for clinicians reviewing unexplained high white counts.
The Genetic Driver: CSF3R Mutations
The single most important advance in CNL research has been the discovery of activating mutations in CSF3R — the gene encoding the receptor for granulocyte colony-stimulating factor (G-CSF). About 90% of CNL patients carry a CSF3R mutation, most commonly the specific variant CSF3R T618I.
Why does this matter clinically?
- It confirms the diagnosis. WHO 2022 criteria require either a demonstrated CSF3R mutation or, in its absence, persistent neutrophilia for at least three months plus splenomegaly with no other identifiable cause.
- It predicts drug response. Depending on exactly where the mutation sits on the CSF3R gene, the cancer cells signal either through the JAK-STAT pathway (sensitive to JAK inhibitors like ruxolitinib) or through SRC-family/TNK2 kinases (sensitive to dasatinib instead). In other words, the mutation subtype can tell doctors which targeted drug is more likely to work — a textbook example of precision medicine in a rare cancer.
- It carries prognostic weight. CSF3R T618I-driven CNL tends to behave more aggressively than CNL driven by other CSF3R variants, and co-occurring mutations (such as ASXL1) further worsen the outlook.
How Is CNL Diagnosed?
Because CNL mimics far more common conditions, diagnosis is a careful process of exclusion:
- Rule out reactive causes: infection, inflammation, and other secondary triggers of neutrophilia
- Rule out other MPNs: CML, polycythemia vera, primary myelofibrosis
- Confirm counts: white blood cell count typically ≥25 × 10⁹/L (or ≥13 × 10⁹/L under newer ICC criteria for CSF3R-mutated cases), with neutrophils making up ≥80% of the count and fewer than 10% immature precursor cells
- Bone marrow examination: hypercellular marrow dominated by mature neutrophilic cells, with blasts under 5%
- Molecular testing: CSF3R mutation analysis, alongside BCR-ABL1 testing to exclude CML
Prognosis
CNL is an aggressive disease despite its chronic-sounding name. Median overall survival after diagnosis is approximately 1.8 years, and 10–20% of patients eventually transform to acute myeloid leukemia (AML), typically within 3–94 months (average around 21 months) of diagnosis.
Treatment: Where We Stand Today
Because CNL is so rare, there is no single globally standardized treatment protocol — but a clear treatment philosophy has emerged over the last decade, formalized in guidelines such as Onkopedia’s CNL treatment algorithm.
Conventional approaches:
- Cytoreductive drugs like hydroxyurea to control white cell counts
- Targeted chemotherapy in select cases
- Allogeneic stem cell transplantation — currently the only potentially curative option, generally reserved for younger, fit patients
The targeted therapy shift: The discovery of CSF3R mutations transformed CNL from a disease managed purely by symptom control into one where genotype can guide therapy. A landmark case described dramatic clinical improvement in a CSF3R-mutated CNL patient treated with the JAK1/2 inhibitor ruxolitinib — a finding that led to a formal Phase II clinical trial.
That trial (published in the Journal of Clinical Oncology) tested ruxolitinib in 44 patients with CNL and atypical CML. The results confirmed that ruxolitinib was more active in CNL than in atypical CML, and activity was strongest in patients carrying the CSF3R T618I mutation — direct evidence that mutation testing should inform treatment choice.
Researchers have also explored JAK1-selective inhibitors and dasatinib as alternatives tailored to the specific CSF3R mutation subtype (membrane-proximal vs. truncation mutations), reinforcing that CNL treatment is moving toward a genotype-first model.
It’s worth noting this isn’t a fully solved problem: case reports describe patients with co-occurring CSF3R and SETBP1 mutations showing resistance to ruxolitinib, and clonal evolution during treatment has been documented — meaning ongoing molecular monitoring matters even after treatment starts.
The India Context
CNL remains exceptionally rare in Indian clinical practice, and most of the published Indian literature consists of individual case reports rather than large cohort studies — including reports from centers like B.J. Medical College, Pune, describing the classic CNL triad of splenomegaly, sustained neutrophilic leukocytosis, and elevated vitamin B12, with cytogenetic confirmation ruling out CML.
India does not yet have a distinct national CNL treatment protocol; management generally follows the international WHO/ICC diagnostic framework and Onkopedia treatment guidance. Ruxolitinib is already approved and available in India for other MPNs (myelofibrosis, polycythemia vera), making off-label use feasible in confirmed CSF3R-mutated CNL cases where a specialist deems it appropriate — though robust India-specific outcome data is still limited.
What has changed meaningfully in recent years is access to molecular diagnostics. Next-generation sequencing and targeted mutation panels — including CSF3R testing — are increasingly available through Indian diagnostic laboratories, no longer requiring samples to be sent overseas. This matters because CNL’s diagnosis and treatment selection both hinge on getting this specific genetic test done early and accurately.
The Takeaway
CNL illustrates a broader shift in hematology: a disease that used to be managed by “wait and control symptoms” is increasingly approached as “test the mutation, then match the drug.” For patients with unexplained, persistent high neutrophil counts and splenomegaly, timely CSF3R mutation testing isn’t just a diagnostic checkbox — it’s the step that opens the door to targeted therapy options like ruxolitinib.
Part 2: Hereditary CSF3R Neutrophilia — When a High Neutrophil Count Runs in the Family
Most doctors are trained to interpret a persistently high neutrophil count as one of a handful of things: an infection, an inflammatory flare, a reaction to medication, or — in the rare worst case — an acquired blood cancer like the CNL described above. There is a fourth possibility that gets missed far more often than it should: the neutrophilia was never acquired at all. It was inherited.
Hereditary CSF3R neutrophilia is a distinct, familial condition in which a mutation in the CSF3R gene is present from birth — passed down through generations — rather than arising spontaneously later in life the way it does in CNL. Recognizing this distinction changes how a family gets counseled, monitored, and tested.
Two Very Different Ways to Get the Same Mutation
The CSF3R gene encodes the receptor for granulocyte colony-stimulating factor (G-CSFR), the signal that tells the bone marrow to keep producing neutrophils. When this gene carries an activating mutation, the receptor essentially gets stuck signaling “make more neutrophils” even without the normal trigger.
There are two distinct routes to this same molecular outcome:
- Somatic (acquired) mutation — arises later in life within a single clone of bone marrow cells, as seen in Chronic Neutrophilic Leukemia. Not present at birth, not passed to children.
- Germline (hereditary) mutation — present in every cell of the body from conception, inherited from a parent or arising as a new mutation early in embryonic development. This form can be passed on to the next generation.
The clinical picture can look almost identical at a glance — high white cell count, neutrophil-dominant differential, sometimes an enlarged spleen — which is exactly why family history and genetic testing are the only reliable ways to tell them apart.
The Genetics: Not All CSF3R Mutations Behave the Same Way
Research has identified more than one hereditary CSF3R variant, and where the mutation sits on the gene matters enormously:
- CSF3R T618I (also referenced as T595I in some older nomenclature) is the most extensively studied variant. It has been documented as a spontaneous germline mutation in children, and — significantly — as an inherited mutation passed through a multi-generation family, confirming true hereditary transmission of this specific hotspot.
- CSF3R T640N (formerly annotated T617N) is a separate transmembrane-domain mutation identified in a large family pedigree, transmitted in an autosomal dominant pattern with complete penetrance — meaning every family member who inherited the mutation went on to develop the trait.
- Documented pediatric case series describe a father and daughter both carrying the same germline CSF3R T618I mutation, with the father’s own lifelong unexplained high white count going undiagnosed until his 30s — decades after it likely began.
This last point deserves attention: the literature repeatedly shows that hereditary CSF3R neutrophilia can go unrecognized for an entire adult lifetime, dismissed as “just how someone’s blood count runs,” until a child’s diagnostic workup finally traces the mutation back through the family tree.
Why the Distinction Actually Matters
Telling hereditary CSF3R neutrophilia apart from CNL isn’t an academic exercise — it changes real decisions:
1. It reframes the conversation from “cancer” to “trait” (usually). A germline CSF3R mutation on its own is not equivalent to a leukemia diagnosis. Some documented carriers live with stable, lifelong elevated neutrophil counts and no disease progression. That said, ongoing monitoring matters, since the same molecular pathway that drives benign hereditary neutrophilia can also predispose to clonal evolution over time in some individuals — this is an area of active research, not a settled question.
2. It identifies who else in the family should be tested. If a mutation is germline, it follows inheritance patterns — parents, siblings, and children carry a defined probability of also carrying it. A single diagnosis in one family member is a signal to trace the mutation across the pedigree, rather than treating the case as isolated.
3. It prevents an unnecessary cascade of investigations. Without genetic confirmation, a lifelong elevated neutrophil count can trigger repeated, invasive workups over the years — bone marrow biopsies, imaging, oncology referrals — each time re-investigating something that a single genetic test could have already explained.
4. It still matters for treatment planning if disease does emerge. Should a carrier of a germline CSF3R mutation go on to develop clinical CNL, knowing the exact mutation subtype helps guide whether JAK inhibitor therapy (for membrane-proximal/extracellular domain mutations like T618I and T640N) is likely to be effective — the same genotype-to-drug logic used in acquired CNL.
The India Angle: Why Family History Gets Lost
In Indian clinical practice, hereditary blood disorders face a specific pattern of underrecognition:
- Multi-generational family health information is often incomplete or anecdotal, especially across joint families where “always had a high count” gets treated as a personal quirk rather than a documented, testable trait.
- Persistent neutrophilia discovered on a routine CBC in India is still most commonly worked up first for infection (especially given a higher baseline burden of infectious disease), delaying the recognition of a purely genetic cause.
- Genetic counseling as a formal step — building an actual pedigree chart before ordering a hereditary panel — is a newer addition to Indian diagnostic workflows, but it is precisely the step that distinguishes an inherited CSF3R mutation from an acquired one.
- As NGS-based testing has become available domestically in Indian laboratories rather than requiring samples to be couriered abroad, turnaround time and accessibility for confirming hereditary CSF3R neutrophilia have improved substantially — making family-wide testing far more practical than it was even five years ago.
What a Proper Workup Looks Like
Confirming hereditary CSF3R neutrophilia is not just about running a gene panel in isolation. A rigorous approach includes:
- A detailed clinical history of the affected individual, including how long the elevated count has been present and at what age it was first noted
- A pedigree chart — mapping which relatives have a known or suspected history of unexplained high white cell counts, splenomegaly, or related symptoms
- NGS-based CSF3R gene sequencing, run alongside exclusion of BCR-ABL1 and other acquired MPN drivers
- Interpretation of the result in the context of family pattern — a mutation found only in one individual, with parents testing negative, points toward a de novo (new, non-inherited) germline event rather than transmitted hereditary neutrophilia; a mutation traced through multiple relatives confirms true familial transmission
The Takeaway
An unexplained, persistently high neutrophil count that has been “normal for this family for years” is not a diagnosis — it’s an unanswered question. Hereditary CSF3R neutrophilia sits in a genuinely underdiagnosed space between “nothing to worry about” and “chronic neutrophilic leukemia,” and the only way to know which side of that line a family falls on is molecular confirmation, built on a proper clinical and family history.
For individuals or families with a documented pattern of unexplained neutrophilia across generations, CSF3R gene NGS testing is the diagnostic step that turns a family anecdote into a confirmed — or ruled out — genetic finding.
Closing Thought
Whether the origin is acquired (CNL) or inherited (hereditary CSF3R neutrophilia), the path forward starts the same way: don’t treat a persistently high neutrophil count as a mystery to be managed indefinitely. Test the gene, understand the mutation, and let the molecular result — not just the blood count — guide what happens next.
FAQ
1. What is Chronic Neutrophilic Leukemia (CNL)? CNL is a rare blood cancer classified as a myeloproliferative neoplasm (MPN), in which the bone marrow produces too many neutrophils. It is BCR-ABL1-negative, distinguishing it from chronic myeloid leukemia (CML).
2. What causes CNL? About 90% of CNL cases are driven by an activating mutation in the CSF3R gene, most commonly the CSF3R T618I variant, which causes uncontrolled neutrophil production.
3. What are the early symptoms of CNL? Many cases are found incidentally on a routine CBC with no symptoms at all. When symptoms do appear, they typically include an enlarged spleen (splenomegaly), fatigue, itching, easy bruising, bone pain, and occasionally gout.
4. How is CNL diagnosed? Diagnosis involves ruling out infections and other reactive causes, excluding other MPNs like CML, confirming elevated neutrophil counts on blood work, examining the bone marrow, and confirming a CSF3R mutation through molecular testing.
5. Is CNL curable? Allogeneic stem cell transplantation is currently the only potentially curative option, generally reserved for younger, fit patients. Other treatments, including ruxolitinib for CSF3R-mutated cases, help manage the disease and improve outcomes.
6. What is the prognosis for CNL? CNL is aggressive despite its “chronic” name. Median overall survival is approximately 1.8 years, and 10–20% of patients eventually progress to acute myeloid leukemia (AML).
7. Does CSF3R mutation testing affect CNL treatment? Yes. The exact CSF3R mutation subtype helps determine whether a patient is likely to respond to JAK inhibitors like ruxolitinib or to alternatives like dasatinib, making mutation testing central to treatment selection.
8. What is Hereditary CSF3R Neutrophilia, and how is it different from CNL? Hereditary CSF3R neutrophilia is a familial condition where a CSF3R mutation is inherited and present from birth, unlike CNL, where the mutation is acquired later in life within bone marrow cells. Both can cause similar blood count changes, but only the hereditary form runs in families and can be passed to children.
9. Can a high neutrophil count be genetic and run in families? Yes. Hereditary CSF3R neutrophilia is passed down in an autosomal dominant pattern in documented families, meaning parents, siblings, and children of an affected individual may also carry the mutation and should be evaluated.
10. Who should consider CSF3R genetic testing? Individuals with persistently high neutrophil counts and splenomegaly with no clear infectious or inflammatory cause, and families with a documented multi-generational pattern of unexplained high white cell counts, are strong candidates for CSF3R gene testing to distinguish an acquired condition like CNL from an inherited trait.
11. Is CNL common in India? No, CNL remains exceptionally rare in Indian clinical practice, with most published cases limited to individual case reports. However, access to CSF3R molecular testing through Indian diagnostic laboratories has improved significantly, removing the earlier need to send samples abroad.
12. What does a hereditary CSF3R neutrophilia workup involve? A proper workup includes a detailed clinical history, a pedigree chart mapping affected relatives, NGS-based CSF3R gene sequencing, and exclusion of BCR-ABL1 and other acquired MPN drivers, with results interpreted in the context of family testing patterns.
This article is intended for general educational purposes and does not constitute medical advice. Individuals with a personal or family history of unexplained neutrophilia should consult a hematologist or genetic counselor to determine whether testing is appropriate.
